Literature DB >> 19164787

Danqi Piantang Jiaonang (DJ), a traditional Chinese medicine, in poststroke recovery.

Christopher Chen1, N Venketasubramanian, Robert N Gan, Caroline Lambert, David Picard, Bernard P L Chan, Edwin Chan, Marie G Bousser, Shi Xuemin.   

Abstract

BACKGROUND AND
PURPOSE: Stroke is a leading cause of death and disability worldwide. Despite improvements in acute stroke treatment, many patients only make a partial or poor recovery. Therefore, there is a need for treatments that would further improve outcome. Danqi Piantang Jiaonang (DJ; NeuroAid), a traditional Chinese medicine widely used in China to improve recovery after stroke, has been compared with another traditional Chinese medicine in 2 unpublished randomized clinical trials. The results of these studies were pooled and reanalyzed to assess efficacy and safety.
METHODS: Six hundred five subjects were randomized in 2 randomized double-blinded, controlled trials to receive either DJ or Buchang Naoxintong Jiaonang. Subjects were treated for 1 month. Inclusion criteria were: (1) patients with recent (from 10 days to 6 months) ischemic stroke; (2) patients satisfying Western diagnostic standards for stroke and traditional Chinese medicine standards for diagnosis of apoplexy; and (3) Diagnostic Therapeutic Effects of Apoplexy score >/=10.
RESULTS: The functional outcome, measured by the Comprehensive Function Score component of the Diagnostic Therapeutic Effects of Apoplexy scale, showed a statistically significant superiority of DJ over the control treatment group (relative risk, 2.4; 95% CI, 1.28 to 4.51; P=0.007). Tolerance was excellent in both groups.
CONCLUSIONS: The pooled analysis of 2 unpublished trials of DJ, a traditional Chinese medicine currently approved in China to improve neurological recovery after stroke, shows good tolerability and superiority of DJ over another traditional Chinese medicine also approved for stroke. A large double-blind randomized clinical trial is required to further assess the safety and efficacy of DJ.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19164787     DOI: 10.1161/STROKEAHA.108.531616

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  29 in total

1.  Comparison of Aspirin and Naoxintong Capsule () with Adjusted-Dose Warfarin in Elderly Patients with High-Risk of Non-Valvular Atrial Fibrillation and Genetic Variants of Vitamin K Epoxide Reductase.

Authors:  Huan Wang; Xiao-Kai Zhou; Li-Fan Zheng; Xiao-Ying Wu; Hui Chen
Journal:  Chin J Integr Med       Date:  2016-02-26       Impact factor: 1.978

Review 2.  Evidence-based practice of Chinese medicine in physical rehabilitation science.

Authors:  Arthur de Sá Ferreira
Journal:  Chin J Integr Med       Date:  2013-03-16       Impact factor: 1.978

3.  A randomized trial to assess the long-term safety of NeuroAiD among Caucasian patients with acute ischemic stroke.

Authors:  Reza Bavarsad Shahripour; Ahmad Hemati; Ana Hosseinzadeh Maleki
Journal:  Chin J Integr Med       Date:  2014-04-02       Impact factor: 1.978

4.  Efficacy of dual antiplatelet therapy combined with Naoxintong capsules [see text] following coronary microembolization induced by homologous microthrombi in rats.

Authors:  Huan Wang; Wen-juan Zhong; Ming-wei Huang; Xiao-ying Wu; Hui Chen
Journal:  Chin J Integr Med       Date:  2011-12-03       Impact factor: 1.978

5.  Therapeutic efficacy of Neuro AiD™ (MLC 601), a traditional Chinese medicine, in experimental traumatic brain injury.

Authors:  Ming-Che Tsai; Ching-Ping Chang; Syue-Wei Peng; Kai-Sheng Jhuang; Yi-Hsien Fang; Mao-Tsun Lin; Thomas Chang-Yao Tsao
Journal:  J Neuroimmune Pharmacol       Date:  2014-10-21       Impact factor: 4.147

6.  NeuroAid II (MLC901) in Haemorrhagic Stroke.

Authors:  Chai-Hoon Nowel Tan; David Choy; Narayanaswamy Venketasubramanian
Journal:  Case Rep Neurol       Date:  2020-12-14

7.  A pharmacogenomic profile of human neural progenitors undergoing differentiation in the presence of the traditional Chinese medicine NeuroAiD.

Authors:  H Y A Chan; L W Stanton
Journal:  Pharmacogenomics J       Date:  2016-04-05       Impact factor: 3.550

8.  Comparison of Adjunctive Naoxintong versus Clopidogrel in Volunteers with the CYP2C19*2 Gene Mutation Accompanied with Qi Deficiency and Blood Stasis Constitution.

Authors:  Hui Chen; Guangwei Yu; Hong Sun; Xiaoying Wu; Huan Wang
Journal:  Evid Based Complement Alternat Med       Date:  2011-03-01       Impact factor: 2.629

Review 9.  Traditional Chinese medicines in the management of cardiovascular diseases: a comprehensive systematic review.

Authors:  Kerry Layne; Albert Ferro
Journal:  Br J Clin Pharmacol       Date:  2016-06-17       Impact factor: 4.335

10.  The Use of NeuroAiD (MLC601) in Postischemic Stroke Patients.

Authors:  Jose C Navarro; Mark C Molina; Alejandro C Baroque Ii; Johnny K Lokin
Journal:  Rehabil Res Pract       Date:  2012-12-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.